Soligenix, Inc. — Form 10-Q Summary
Reporting period: Three and nine months ended September 30, 2016. Soligenix is a development-stage biopharmaceutical company with BioTherapeutics and Vaccines/BioDefense segments. Revenue was generated primarily from government contracts and grants; the filing reports no product sales.
Financial results and liquidity
| Metric | Q3 2016 | Q3 2015 | Nine months 2016 | Nine months 2015 |
|---|---|---|---|---|
| Revenue | $2.96 million | $3.88 million | $8.75 million | $5.80 million |
| Gross profit (margin) | $0.33 million (11%) | $0.83 million (21%) | $1.55 million (18%) | $1.40 million (25%) |
| Operating expenses | $1.83 million | $2.10 million | $5.96 million | $6.26 million |
| Operating loss | $1.50 million | $1.27 million | $4.41 million | $4.86 million |
| Net income (loss) | $(1.67) million | $2.77 million | $(2.92) million | $(5.77) million |
- Nine-month revenue increased 51%, reflecting increased activity under OrbeShield and RiVax government contracts. Q3 revenue declined 24%, partly because certain fixed and management fees depend on development milestones.
- Nine-month gross margin declined to 18% from 25%; management attributed the lower rate to a higher proportion of reimbursable costs that do not earn fixed management fees. R&D expense fell 8% year over year, principally following completion of SGX942 Phase 2 enrollment and reduced pediatric Crohn’s manufacturing activity.
- Q3 2015 net income included a $4.05 million non-cash warrant fair-value gain. For the first nine months of 2016, other income included a $1.11 million warrant fair-value gain and a $0.39 million reversal of a previously accrued liability. These items materially affect comparisons of net results.
- Cash and equivalents were $5.66 million at September 30, 2016, versus $4.92 million at December 31, 2015. Nine-month operating cash use was $3.56 million; investing cash use was $0.01 million and financing provided $4.30 million. Financing included $3.00 million from SciClone and $1.64 million from Lincoln Park equity-line stock sales, before associated issuance costs.
- Working capital was $3.32 million when excluding the $1.32 million non-cash warrant liability. Current assets were $7.58 million and current liabilities were $5.58 million. Notes payable were fully repaid during 2016; no notes payable remained at quarter-end. Total assets were $7.75 million and shareholders’ equity was $2.17 million.
Material changes, outlook and risks
- In September 2016, Soligenix licensed SGX942 development and commercialization rights in China, Hong Kong, Macau, Taiwan, South Korea and Vietnam to SciClone. SciClone is responsible for development and commercialization in the territory; Soligenix is entitled to royalties on net sales and will supply commercial product on a cost-plus basis. Separately, SciClone purchased 352,942 shares for $3.00 million.
- Management expected cash, government-contract and grant proceeds, equity facilities and New Jersey tax-loss-sale proceeds to fund working capital and capital expenditures for at least 12 months. This assessment depends on future funding and financing sources being available. Management cited up to $35.1 million of government funding still available, conditional on agencies exercising options and not terminating agreements, and expected approximately $530,143 from New Jersey NOL sales in 2016.
- For the next 12 months, the company estimated gross R&D spending of approximately $12.0 million, including $5.8 million for BioTherapeutics and $6.2 million for Vaccines/BioDefense, and anticipated approximately $6.2 million in contract and grant revenue to offset Vaccines/BioDefense R&D costs. These are estimates, not assured funding or results.
- Clinical and development plans included completing enrollment and reporting preliminary Phase 3 SGX301 results, with data expected in the second half of 2017; seeking FDA agreement on a pivotal SGX942 protocol; and planning a Phase 3 SGX203 trial for the first half of 2017. Programs and timelines are subject to funding, regulatory and clinical risks.
- In October 2016, the company effected a one-for-ten reverse stock split. In November, holders of the 2013 warrants agreed to reduce the post-split exercise price from $5.10 to $0.80, allow cashless exercise and eliminate the down-round provision. The amendment reduced the warrant liability by approximately $430,000 and reclassified it to equity; 33,978 shares had been issued through November 9 following cashless exercises.
- Potential obligations include licensing commitments of approximately $416,667, leases, and up to $7.9 million of development/commercialization milestones plus royalties of up to 6% of net sales if applicable milestones or sales occur. A separate hypericin asset agreement provides for up to $10.0 million of success-based payments. None of these milestone or royalty amounts had been paid or accrued at September 30.
- Key risks include continued reliance on government funding and equity financing, possible share dilution, clinical-trial and FDA outcomes, the early-stage nature of the pipeline, and the possibility that contract options or partnership opportunities do not materialize. Management reported disclosure controls were effective at a reasonable-assurance level and no material quarterly change in internal control over financial reporting.
Important facts for investors to verify
- Whether government agencies exercise contract options and whether anticipated grant, contract and NOL-sale proceeds are received on schedule.
- Actual cash burn, available equity-facility capacity and terms, and the timing and pricing of any additional financing.
- SGX301 Phase 3 enrollment and data timing, FDA discussions and development milestones for SGX942 and SGX203.
- The financial and development terms of the SciClone license, including any royalty receipts and commercial supply obligations.
- The effects of the warrant amendment and subsequent exercises on reported equity, share count and potential dilution.